Fusion Pharmaceuticals Inc.

NasdaqGS:FUSN Stock Report

Market Cap: US$1.8b

Fusion Pharmaceuticals Valuation

Is FUSN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FUSN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FUSN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FUSN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for FUSN?

Key metric: As FUSN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for FUSN. This is calculated by dividing FUSN's market cap by their current book value.
What is FUSN's PB Ratio?
PB Ratio7.6x
BookUS$241.83m
Market CapUS$1.83b

Price to Book Ratio vs Peers

How does FUSN's PB Ratio compare to its peers?

The above table shows the PB ratio for FUSN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
CLDX Celldex Therapeutics
2.3x1.1%US$1.8b
NRIX Nurix Therapeutics
4.1x-2.3%US$1.6b
DCPH Deciphera Pharmaceuticals
7x50.6%US$2.2b
ZLAB Zai Lab
3.9x68.2%US$2.6b
FUSN Fusion Pharmaceuticals
7.6x0.1%US$1.8b

Price-To-Book vs Peers: FUSN is expensive based on its Price-To-Book Ratio (7.6x) compared to the peer average (4.1x).


Price to Book Ratio vs Industry

How does FUSN's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
FUSN 7.6xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: FUSN is expensive based on its Price-To-Book Ratio (7.6x) compared to the US Biotechs industry average (2.1x).


Price to Book Ratio vs Fair Ratio

What is FUSN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FUSN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate FUSN's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FUSN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Nov ’25n/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Oct ’25n/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Sep ’25n/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Aug ’25n/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Jul ’25n/a
US$21.10
0%
0.9%US$21.50US$21.00n/a5
Jun ’25US$21.52
US$20.95
-2.6%
5.5%US$23.00US$18.00n/a10
May ’25US$21.42
US$21.23
-0.9%
6.6%US$24.00US$18.00n/a11
Apr ’25US$21.25
US$21.23
-0.1%
6.6%US$24.00US$18.00n/a11
Mar ’25US$11.99
US$14.58
+21.6%
23.8%US$20.00US$10.00n/a12
Feb ’25US$11.12
US$14.58
+31.1%
23.8%US$20.00US$10.00n/a12
Jan ’25US$9.61
US$13.27
+38.1%
26.9%US$20.00US$9.00n/a11
Dec ’24US$5.35
US$13.10
+144.9%
28.2%US$20.00US$9.00n/a10
Nov ’24US$4.58
US$13.10
+186.0%
28.2%US$20.00US$9.00n/a10
Oct ’24US$2.60
US$13.10
+403.8%
28.2%US$20.00US$9.00n/a10
Sep ’24US$2.93
US$13.11
+347.5%
29.7%US$20.00US$9.00n/a9
Aug ’24US$3.27
US$13.22
+304.3%
29.4%US$20.00US$9.00n/a9
Jul ’24US$4.67
US$13.22
+183.1%
29.4%US$20.00US$9.00n/a9
Jun ’24US$5.02
US$14.00
+178.9%
32.3%US$20.00US$9.00US$21.528
May ’24US$4.10
US$13.88
+238.4%
31.5%US$20.00US$9.00US$21.428
Apr ’24US$3.77
US$13.88
+268.0%
31.5%US$20.00US$9.00US$21.258
Mar ’24US$4.42
US$13.63
+208.3%
30.2%US$20.00US$9.00US$11.998
Feb ’24US$3.18
US$12.75
+300.9%
35.7%US$20.00US$6.00US$11.128
Jan ’24US$3.15
US$13.30
+322.2%
36.4%US$20.00US$6.00US$9.619
Dec ’23US$2.29
US$12.46
+444.2%
35.9%US$19.00US$6.00US$5.358
Nov ’23US$2.47
US$13.95
+464.8%
29.1%US$19.00US$8.70US$4.586

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies